Lymphoma of the ankle. Really? (cont)

Continued from the previous part …

BACK TO THE ANKLE

Since I don't subscribe to the Journal of the American Podiatric Medical Association, I plunked down $5 to gain 24-access to the paper because the abstract gave up little information and frankly I wanted to know how it ended.

Answer: Not well.

First, they surgically removed the ankle tumor, which weighed an impressive 60 grams (see pic above, if you're willing). A sample went straight to pathology where they learned it was a lymphoma. Further testing revealed it to be DLBCL, and later testing showed that it had completely metastasized—the poor woman was drowning in lesions. Despite chemo and radiation, the patient died seven months after surgery.

Not what I was expecting, especially considering that this massive ankle tumor was the woman's first indication of any trouble. Not only that, but eight months before the surgery, her ankle looked normal.

DLBCL EXPLAINED

So how could it be diffuse large B-cell lymphoma?

Because on its face DLBCL is, like all lymphomas, just a histological description that barely transcends the most basic of information:

diffuse = widely spread through a tissue sample (not localized)
large = large cell size, as in larger than surrounding healthy cells
b-cell = the lymphocyte in question
lymph— = grammatical prefix indicating the lymphatic system, part of the immune system.
—oma = grammatical suffix indicating cancer (sarcoma, carcinoma, melanoma etc).

The potentially enormous cytogenetic disparity between any two cases of DLBCL is likely the reason why standard treatment for the subtype—six cycles of R-CHOP followed by radiation—is ineffective for some patients.

As a microbiologist recently said to me, a single protein expression on the surface of a cancer cell can mean the difference between one of us beating cancer and the other not beating cancer.

Finally, there was no evidence in the paper that doctors ever determined the true primary site. Cancer of unknown primary origin currently constitutes one of the most prevalent cancers in the world, accounting for as much as 5% of all diagnoses.

This person's cancer very likely could have started anywhere, since the lymph system traverses the entire body, and the body features hundreds of lymph nodes, it becomes possible for lymphoma—for cancerous lymphocytes I mean—to develop anywhere and become trapped in any one of those nodes.

Her lymphoma just happened to first present itself in the ankle.

Hence, DLBCL of the ankle.

ANATOMICALLY INCORRECT

Fortunately, researchers are slowly moving away from approaching cancer as an anatomical disease—breast, liver, bone, lung—and toward cancer as a molecular one, few places better illustrated than in the recent story of a Vancouver man whose resilient tongue cancer turned out to be, after sequencing the tumor's genome, a lot less like oral cancer and a whole lot more like renal cell carcinoma.

i.e. kidney cancer.

By Ross Bonander
Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap